ADAP Adaptimmune Therapeutics
- 1.180
- +0.105+9.77%
Adaptimmune Therapeutics News
Adaptimmune Therapeutics Plc (NASDAQ:ADAP) Not Doing Enough For Some Investors As Its Shares Slump 30%
The Adaptimmune Therapeutics plc (NASDAQ:ADAP) share price has softened a substantial 30% over the previous 30 days, handing back much of the gains the stock has made lately.
European Equities Traded in the US as American Depositary Receipts Jump in Tuesday Trading
European equities traded in the US as American depositary receipts jumped Tuesday morning, advancing 1.31% to 1,362.51 on the S&P Europe Select ADR Index. From continental Europe, the gainers were led
Garry Menzel Joins GHO Capital as Operating Partner
Garry Menzel joins GHO Capital as Operating Partner Former CEO of TCR2 Therapeutics with significant investment and operating experience to support deal origination and provide best in class services to pioneering
Leerink Partners Sticks to Its Hold Rating for Adaptimmune Therapeutics (ADAP)
12 Health Care Stocks Moving In Friday's After-Market Session
GainersMobile-health Network (NASDAQ:MNDR) shares rose 15.0% to $31.35 during Friday's after-market session. The company's market cap stands at $1.0 billion. Galera Therapeutics (NASDAQ:GRTX) stock in
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down
European equities traded in the US as American depositary receipts were trending higher Friday morning, rising 0.46% to 1,330.20 on the S&P Europe Select ADR Index. Despite the gain, the index remains
Analysts Have Conflicting Sentiments on These Healthcare Companies: Elevance Health (ELV) and Adaptimmune Therapeutics (ADAP)
European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading
European equities traded in the US as American depositary receipts were treading water in Thursday morning session, nudging 0.006% higher to 1,330.06 on the S&P Europe Select ADR Index. From continent
Maintaining Buy Rating on Adaptimmune Therapeutics Post-Genentech Collaboration Termination
Analysts Offer Insights on Healthcare Companies: Adaptimmune Therapeutics (ADAP) and Immunic (IMUX)
Hedge Funds Owners May Take Dramatic Actions as Adaptimmune Therapeutics Plc's (NASDAQ:ADAP) Recent 15% Drop Adds to One-year Losses
Key Insights Significantly high institutional ownership implies Adaptimmune Therapeutics' stock price is sensitive to their trading actions The top 4 shareholders own 56% of the company Recent sa
Express News | Adaptimmune Therapeutics Shares Are Trading Lower After the Company Said It Received Notice of Termination of the Strategic Collaboration and License Agreement With Genentech and F. Hoffman-La Roche Ltd
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading
European equities traded in the US as American depositary receipts were lower Friday morning, falling 0.66% to 1,356.48 on the S&P Europe Select ADR Index. The index is poised to close the week down n
Express News | Adaptimmune Therapeutics Shares Down 3.5% After Roche's Genentech Terminates Deal With Co to Develop Cancer Therapies
Adaptimmune Slips as Roche Strategic Collaboration Ends
Express News | Adaptimmune Therapeutics Says On April 10, Unit Of Co, Received Notice Of Termination Of Strategic Collaboration And License Agreement With Genentech; Termination Will Become Effective 180 Days After Date Of Receipt; As Result Of Termination, Co Not Entit
Express News | Adaptimmune Therapeutics PLC: Will Also Cease to Have Any Development Obligations After Termination Date
Express News | Adaptimmune Therapeutics PLC: as a Result of Termination, Co Not Entitled to Receive Further Milestones or Other Payments Due After Termination Date
Express News | Adaptimmune Therapeutics PLC: Termination Will Become Effective 180 Days After Date of Receipt of Notice of Termination
Express News | Adaptimmune Therapeutics : on April 10, Unit of Co, Received Notice of Termination of Strategic Collaboration and License Agreement With Genentech
Analysis
Price Target
No Data
